Core Viewpoint - The company announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd., has proposed to be selected for the national centralized procurement of clarithromycin tablets and simvastatin tablets, with the procurement period extending until December 31, 2028 [1] Group 1 - The total sales revenue for the two products in 2024 is projected to be 38.99 million yuan, which accounts for 11.81% of the company's total revenue [1] - If the purchase and sales agreement is signed, it will expand the sales scale of the company [1]

Investment Rating - The industry investment rating is "Overweight (Maintain)" [4] Core Insights - The recent results of the national centralized procurement for batches 1-8 have been released, which is expected to benefit leading companies with scale effects, particularly those integrated in raw material and formulation production [6] - The procurement process involved 5.1 million medical institutions and 1,091 domestic and foreign companies, with 4,163 products selected from 1,020 companies, indicating a high participation rate and a stable supply of selected products [6] - The procurement cycle is set to last until the end of 2028, allowing selected companies to secure a three-year national market, which is beneficial for capacity planning and cost optimization [6] Summary by Sections Industry Overview - The industry comprises 502 listed companies with a total market value of 73,023.15 billion yuan and a circulating market value of 67,026.08 billion yuan [2] Procurement Results - The procurement covers 316 commonly used drugs across 26 therapeutic areas, with a high selection rate of 93% for participating companies [6] - The average number of selected companies per product is 14, ensuring a diverse supply base and rich clinical choices [6] Competitive Landscape - The procurement reflects a shift in policy from "price reduction and expansion" to "price stability and quality assurance," favoring leading companies with compliance capabilities and scale advantages [6] - Companies like Huahai Pharmaceutical and Kelun Pharmaceutical have significant advantages in their respective fields, with high selection rates for major products [6] Future Outlook - The procurement process is expected to stabilize prices and industry expectations, moving the focus from "lowest price competition" to a comprehensive competition based on quality, capacity, compliance, and brand [6] - The new requirements for production experience and compliance are likely to accelerate the exit of smaller, weaker companies from the market [6]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) maintains a stable annual R&D investment of approximately 250-280 million yuan, with a shift in focus towards raw materials and CDMO R&D while decreasing investment in generic drug formulations [1] Group 1: R&D Investment - The company plans to keep its overall R&D investment steady at around 250-280 million yuan each year [1] - There is an increasing proportion of R&D investment allocated to raw materials and CDMO, while the investment in generic drug formulations is gradually declining [1] Group 2: Sales Expenses - The sales expenses for the formulation business are growing rapidly due to its fast development [1] - The company is enhancing its marketing management through the establishment of a digital system [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) emphasizes a differentiated research and development strategy focused on clinical needs, leveraging advanced technology platforms to create a matrix of differentiated innovative products [1] Group 1: Product Development - The company has developed the first-in-class innovative drug, Ruilafup α injection, which was approved for domestic market launch in January 2026, marking it as the world's first approved PD-L1/TGF-βRII bispecific antibody fusion protein [1] - There are over 100 self-innovated products currently in clinical development, including those with potential for first-in-class or best-in-class status [1] Group 2: Future Strategy - The company plans to continue exploring cutting-edge international drug targets that have potential for first-in-class or best-in-class innovations, aiming to continuously produce differentiated and competitively innovative products [1]

Core Viewpoint - Yiming Pharmaceutical announced plans to purchase liability insurance for its directors and executives, with a compensation limit not exceeding 100 million yuan and a premium not exceeding 500,000 yuan for a duration of 12 months [2] Group 1 - The company intends to seek shareholder approval to authorize the management team to handle the insurance purchase and renewal matters [2]

Core Viewpoint - Fuyuan Pharmaceutical announced participation in the national organized procurement for drugs, with a procurement period extending until December 31, 2028 [1] Group 1: Company Participation - The company will be involved in the continuation of procurement for five main products, including Eplerenone tablets, Telmisartan tablets, Gliclazide sustained-release tablets, Olmesartan medoxomil tablets, and Repaglinide tablets [1] - Additionally, the company plans to include eight other drugs, such as Venlafaxine hydrochloride sustained-release capsules, in the procurement process [1]

Core Viewpoint - The company, Anglikang, announced its participation in the national organized procurement for the continuation of products whose agreements have expired, with some of its products being proposed for selection in this procurement process [1]. Group 1 - The company has engaged in the national organized procurement for the first to eighth batches of products whose agreements have expired [1]. - The procurement results were published by the continuation procurement office on February 10, 2026 [1]. - Some of the company's products are proposed to be selected in this continuation procurement [1].

Group 1 - The core viewpoint of the article is that Heng Rui Pharmaceutical has established a financial shared service center to enhance its financial management through digital and intelligent technologies [1] Group 2 - The company aims to improve the standardization, centralization, refinement, and intelligence of its financial management [1]

湖北广济药业（维权）股份有限公司（以下简称"广济药业"）于2026年2月12日发布公告称，公司控股 股东长江产业投资集团有限公司（以下简称"长江产业投资"）已就参与公司2026年度向特定对象发行A 股股票（以下简称"本次发行"）出具相关承诺函，明确拟认购不超9493.67万股股份，并承诺该部分股 份自发行结束之日起36个月内不转让。 据公告披露，广济药业于2026年2月11日召开第十一届董事会第十五次（临时）会议，审议通过了本次 发行的相关议案。作为本次发行的认购对象，长江产业投资在承诺函中表示，同意认购本次发行的不超 过94,936,708股（含本数）股票，该数量不超过本次发行前公司总股本的30%，最终发行数量将以中国 证监会同意注册的数量为准，并由公司股东会授权董事会与保荐机构（主承销商）协商确定。 在发行价格方面，本次发行的定价基准日为第十一届董事会第十五次（临时）会议决议公告日，发行价 格不低于定价基准日前二十个交易日公司股票交易均价的80%。公告同时指出，若在定价基准日至发行 日期间公司发生派发股利、送红股、转增股本等除息、除权事项，发行价格下限将作相应调整。 资金来源方面，长江产业投资明确本次认购 ...

Group 1 - The core viewpoint of the article is that Heng Rui Pharmaceutical is actively monitoring technological advancements in the industry and exploring their auxiliary applications in drug development [1] Group 2 - The company is engaging with investors through interactive platforms to address inquiries regarding its focus on technology [1]